Dishman Carbogen Amcis / Q3-FY26

Read the quarter in context.

A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

Watch2026-01-29Back to DCAL

Revenue

₹720 Cr

verified against source

Revenue YoY

5.5%

reported change

EBITDA

₹113 Cr

latest reported figure

Source

screener in

record provenance

Actual signal trajectory

Where this quarter sits.

source records only
PAT (₹ Cr)PositiveWatchNegative
1 actual records
Actual quarterly PAT (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q3 FY26: -13 · Watch source sentiment · 2026-01-29Q3 FY26-13-13
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Quarter read

What the record says.

Dishman Carbogen Amcis reported Q3 FY26 revenue of ₹720 crore, up 5.5% YoY, but EBITDA margin contracted to 15.7% due to a shift toward lower-margin commercial supplies and early-phase development revenue. The company posted a PAT loss of ₹12.97 crore for the quarter, impacted by a one-time finance cost of ₹11 crore from refinancing. Management maintained its full-year EBITDA margin guidance of 19.5-20%, supported by strong 9M margins of 19.4%. Key growth drivers include a co-investment ADC project with a Japanese customer (revenue expected to rise from CHF 22M in FY25 to CHF 40M in FY27), a ₹1,200 crore RFP pipeline for India operations targeting ₹500 crore revenue in 12-18 months, and a French subsidiary aiming for breakeven in FY27. Risks include delayed customer orders, high India debt of ₹750 crore, and execution dependency on converting RFPs into firm orders.

Colored figures show movement against the previous available record.

Guidance to track

  • Management reaffirmed FY26 EBITDA margin guidance of 19.5-20%, supported by 9M margin of 19.4%.
  • Target to achieve ₹500 crore revenue from India sites within 12-18 months, driven by RFP conversion.
  • French facility expected to break even in FY27 with revenue of €18 million.
  • Plan to reduce India debt of ₹750 crore to zero over the next 3 years using operational cash flows.

Risks flagged

  • A significant portion of growth depends on one Japanese customer's ADC molecule; any loss or delay would materially impact revenue.
  • ₹1,200 crore RFP pipeline may not convert as expected; management acknowledged 30-35% conversion rate and 6-month timeline for visibility.
  • India debt of ₹750 crore carries high interest (~7% higher than Swiss debt), straining cash flows despite deleveraging plans.
  • Business inherently lumpy due to customer shipment timing and revenue mix; Q3 PAT loss highlights unpredictability.

Key quotes

  • We are very well positioned to serve the market and we are optimistic and positive to tackle this and to bring great results in the future as well.
  • The target for the full year still stands. So we could be ending up ending the year with anywhere between 19.5 to 20%.
  • We are seeing a lot of interest for that particular site... we should be breaking even in that particular facility in the next financial year.

Research modules

Go one layer deeper.